Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
June 17, 2024 09:35 ET | Immix Biopharma, Inc.
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in...
Pineapple Interim CEO Adds Shares to His Position
June 17, 2024 09:15 ET | Pineapple Energy
Purchase by Pineapple Energy’s Interim CEO Affirms Commitment to Company’s Goals for Growth
SELLAS Logo.png
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
June 17, 2024 09:05 ET | SELLAS Life Sciences Group, Inc.
–  The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications – –  No Safety or Futility Concerns Were Raised Based on the Efficacy...
LPL Financial logo
LPL Financial Welcomes Russell Wealth Partners
June 17, 2024 09:00 ET | LPL Financial Holdings, Inc.
SAN DIEGO, June 17, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC (Nasdaq: LPLA) announced today that financial advisor Tom Russell, CFP®, and his sons Brian Russell and Charles Russell have joined...
Shineco New Logo.png
Shineco Enters into an Agreement with Turing Video to Jointly Develop Intelligent Health Care Products
June 17, 2024 09:00 ET | Shineco, Inc.
Beijing, June 17, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices announced today...
NVIDIA Omniverse Cloud Sensor RTX
NVIDIA Announces Omniverse Microservices to Supercharge Physical AI
June 17, 2024 09:00 ET | NVIDIA
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- CVPR—NVIDIA today announced NVIDIA Omniverse Cloud Sensor RTX™, a set of microservices that enable physically accurate sensor simulation to accelerate the...
iTeos Logo 2022.png
iTeos und GSK starten Phase-III-Studie GALAXIES Lung-301 zur Untersuchung von Belrestotug und Dostarlimab bei zuvor unbehandeltem, inoperablem, lokal fortgeschrittenem/metastasiertem, PD-L1-selektiertem, nicht-kleinzelligem Lungenkrebs
June 17, 2024 09:00 ET | iTeos Therapeutics Inc.
WATERTOWN, Massachusetts, und GOSSELIES, Belgien, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) („iTeos“), ein im klinischen Stadium tätiges Biopharmazie-Unternehmen, das...
iTeos Logo 2022.png
Début de l’étude GALAXIES Lung-301 de Phase III à l’initiative conjointe d’iTeos et de GSK, visant à évaluer le doublet belrestotug + dostarlimab chez les patients atteints d’un cancer du poumon non à petites cellules PD-L1-positif, localement avancé ou métastatique, non résécable, non préalablement traité
June 17, 2024 09:00 ET | iTeos Therapeutics Inc.
WATERTOWN, État du Massachusetts et GOSSELIES, Belgique, 17 juin 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), ci-après « iTeos », une société biopharmaceutique au stade...
download (2).png
PodcastOne (Nasdaq: PODC) Adds Tactful Pettiness Podcast to Its Network
June 17, 2024 09:00 ET | PodcastOne
- Hosted by Cody Rigsby and Andrew Chappelle - 8th New Podcast Joining PodcastOne Network This Fiscal Year, 39th In Last 12 Months - Total of 184 Shows on the PodcastOne Network - Combined Social...
iTeos Logo 2022.png
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
June 17, 2024 09:00 ET | iTeos Therapeutics Inc.
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and...